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Congenital dyserythropoietic anemia type IV is caused by a heterozy-gous mutation, Glu325Lys (E325K), in the KLF1 transcription factor.Molecular characteristics of this disease have not been clarified, part-
ly due to its rarity. We expanded erythroid cells from a patient’s peripheral
blood and analyzed its global expression pattern. We find that a large num-
ber of erythroid pathways are disrupted, particularly those related to mem-
brane transport, globin regulation, and iron utilization. The altered genetics
lead to significant deficits in differentiation. Glu325 is within the KLF1 zinc
finger domain at an amino acid critical for site specific DNA binding. The
change to Lys is predicted to significantly alter the target site recognition
sequence, both by subverting normal recognition and by enabling interac-
tion with novel sites. Consistent with this, we find high level ectopic
expression of genes not normally present in the red cell. These altered prop-
erties explain patients’ clinical and phenotypic features, and elucidate the
dominant character of the mutation.
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ABSTRACT
Introduction
Congenital dyserythropoietic anemias (CDA) encompass a set of rare, chronic
anemias that are heterogeneous but commonly exhibit morphologically abnormal
bone marrow erythropoiesis. There are four subtypes that are differentiated by
their causative genetic mutations: type I in CDA1, type II in SEC23B, and type III
in KIF23.1-3 The genetic cause for the rare CDA type IV (OMIM 613673) is unique
in that it derives from a transcription factor mutation. A G-to-A transition in one
allele of exon 3 of KLF1 (erythroid Krüppel-like factor; EKLF) results in the substi-
tution of a glutamate 325 by a lysine (E325K). CDA type IV patients present with
severe hemolytic anemia, splenomegaly, elevated fetal hemoglobin (HbF), iron
overload, red cell osmotic fragility, and dyserythropoiesis in the bone marrow.4-13
These clinical properties do not fit into the typical categories for hereditary persist-
ence of fetal hemoglobin, ß-thalassemia, or hereditary spherocytosis.5,12,13 The high
levels of nucleated and bi-nucleated erythroid cells in the bone marrow and in the
peripheral blood are quite striking. 
The E325K mutation, within the second zinc finger of the KLF1 protein, is at a
universally conserved residue/amino acid that is critical for proper DNA target site
recognition. KLF114 is a zinc finger hematopoietic transcription factor that plays a
global role in activation of genes critical for genetic control within the erythroid lin-
eage.15-18 It performs this essential function by binding to its cognate DNA 5’CCM-
CRCCCN3’ element, interacting with basal transcription factors, and recruiting
chromatin remodeling proteins and histone modifiers.
This results in accurate and precise local and global chro-
matin organization. Chromatin immunoprecipitation
sequencing (ChIP-seq) analyses together with RNA
expression profiling underscore the importance of KLF1 in
red cell biology, demonstrating its multifunctional roles in
tissue-specific gene expression, lineage determination, and
terminal maturation.
Over 70 human mutations in KLF1 have been identified
over recent years.19,20 Monoallelic mutation of KLF1 in
humans usually leads to a benign outcome that is
nonetheless phenotypically important.20-24 Expression of
certain cell surface markers, such as CD44 and Lutheran
antigen, are affected but do not exert any physiological
effect.25 Expansion of these cells in culture is also not
affected.10,25 Of clinical importance, however, haploinsuffi-
cient levels of KLF1 lead to altered β-globin switching and
elevated g-globin expression, which can be advantageous,
particularly in areas with endemic β-thalassemia.26 Related
to this, some single and compound mutations in human
KLF1 lead to anemias in addition to CDA such as sphero-
cytosis, microcytic hypochromic anemia, pyruvate kinase
deficiency,10,27,28 or in the most extreme case, hydrops
fetalis.29 Expression of about 700 genes is dependent on
KLF1 in humans. As a result of its central importance, one
might predict an extensive cascade of changes would fol-
low from the KLF1-E325K mutation, particularly likely in
this case given the broad role of KLF1 in the control of ery-
thropoiesis.
Two sets of observations in the mouse are particularly
informative for the present study. One is from studies of
the monoallelic mouse neonatal anemia (Nan) mutation
that resides at the same amino acid of KLF1, albeit with an
aspartate substitution (E339D).30,31 These mice exhibit a
lifelong anemia due to a distorted erythroid transcriptional
output. The E339D mutation not only yields a variant
with a more circumscribed binding specificity compared
to wild type (WT),31 but also one that recognizes a novel,
more degenerate target sequence uniquely recognized by
Nan-KLF1.32,33 The second observation is that, unlike the
Nan mutant, mouse erythroid cells totally ablated in KLF1
do not enucleate, but instead stall at the orthochromatic
erythroblast stage.34 Many of these cells are also bi-nucle-
ated. As a result, mutant expression or insufficient levels
of KLF1 can separately contribute to defective erythroid
expression and phenotypic properties. 
Although the CDA type IV red cell cellular and pheno-
typic properties have been described, the molecular mech-
anism/details by which the KLF1-E325K mutation exerts
its effect and causes these significant changes has not been
previously addressed. A limitation of studying this disease
has been the paucity of starting material due to its rarity.
As a result, we directed our efforts towards analysis of
derived erythroid cells from the peripheral blood of our
published patient.
Methods
Cell sources
Analysis used RNA from patient peripheral blood cells leftover
from our previously published study5 that had received
Institutional Review Board approval; no new patient material was
obtained for the present study. Mononuclear cells from the periph-
eral blood (PBMC) had been isolated and cryopreserved as
described.35 Non-patient PBMC were purchased from AllCells
(PB003F). 
Human erythroid massive amplification protocol
Peripheral blood mononuclear cells underwent a two-step cul-
ture;36,37 one for proliferation, with harvests at day (d)11 and d15;
the second for differentiation that was harvested after the d11
culture was differentiated for an additional five  days. Under
these conditions, the normal sample attained CD235a+ levels of
over 70% (data not shown). As a result, we used these prescreened
reagents and conditions for the proliferation/differentiation
experiment of normal cells in parallel with the patient PBMC
sample. 
Peripheral blood mononuclear cells  (10E6 cells/ml) were cul-
tured in IMDM plus 20% FBS, SCF (100 ng/mL), IL-3 (1 ng/mL),
EPO (5 U/mL), dexamethasone and estradiol (both 1 uM). Also
included were deionized human serum albumin (5%), human
iron saturated transferrin, liposomes plus cholesterol (400
μg/mL), and lecithin (1.2 mg/mL).36,37 Differentiation was enabled
by increasing erythropoietin (EPO) to 10 U/mL, removing dex-
amethasone, and including recombinant human insulin (40
ng/mL) and T3 (1 uM). Both cell sources were successfully cul-
tured and expanded in this way, giving us confidence that the
human erythroid massive amplification (HEMA) approach
enables direct analysis of CDA patient erythroid samples.
Morphological analysis of d11 expanding cells was derived
from analysis of three sets of cytospins from two experiments,
each analyzed and quantified independently by two of the
authors.  
RNA isolation and analysis 
Total RNA from all samples was isolated with Trizol (Sigma).
Bioanalyzer (Agilent) analysis showed that RIN values were all
between 7.8-8.7 except for the normal differentiated d5 sample,
which had a value of 3.4. These samples were used for polyA+
library preparation using the Bioo Scientific (NEXTflex) Rapid
Directional kit (NOVA-5138-07). Next generation sequencing was
performed on an Illumina NextSeq 500. Sequencing yielded 75 nt
single end reads, >30 million per sample. 
RNA-seq data have been submitted to the Gene Expression
Omnibus GSE128718.
Real-time qualitative polymerase chain reaction (RT-qPCR) was
performed on cDNA generated with a mix of oligo-dT and ran-
dom hexamers (Quantabio 95048-025). Primers were as previous-
ly described.38 Errors after combining quantities with their own
uncertainties were calculated as in http://lectureonline.cl.
msu.edu/~mmp/labs/error/e2.htm.
Bioinformatics
Expression data from human in vitro expanded primary ery-
throid cells analyzed at 5 stages (Pimentel, 2014 #2477) was
obtained from GEO (GSE53635). Sequenced reads were mapped
to the human genome (hg38) using Tophat2. Accepted hits were
tested for differential expression analysis using Cuffdiff2 with the
blind dispersion method. Heatmap plots for gene clusters were
created in R package pHeatmap.
Gene set enrichment analysis (GSEA) (http://software.broadinsti-
tute.org/gsea/index.jsp) was performed {Subramanian, 2005
#2464;Mootha, 2003 #2465} using gene set lists from selected
expression clusters (described by Li et al.).39 Venn diagrams were
generated with Venny (http://bioinfogp.cnb.csic.es/tools/venny/ or
https://www.stefanjol.nl/venny) or BioVenn (http://www.
biovenn.nl/index.php) and were used to identify non-overlapping
genes within sets. The DAVID analysis tool v6.8
(https://david.ncifcrf.gov/) was used as described.40
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Results
Establishment of expansion protocol
Our patient had been analyzed with respect to hemato-
logic parameters such as red cell surface expression,
peripheral blood smear, and globin expression pattern.5 For
the present study, erythroid cells were expanded from
PBMC using an ex vivo culture system. This culture system
contains stimulatory cytokines along with the critical
inclusion of dexamethasone to enable efficient expansion
of the small number of erythroid progenitors present in a
typical mononuclear cell preparation.36,37 Using this proto-
col we established and expanded erythroid cells from the
CDA type IV patient in parallel with a normal control.
Morphological examination (Figure 1) reveals that the
expanded patient cells exhibit bi- and multi-nucleated cells
with abnormal nuclei (approx. 40%) as seen in the original
bone marrow and blood smears of the patient.5 These are
observed in approximately 5% of cells from the normal
control. 
Similar to the limitation in studying erythropoiesis in
murine Klf1-null cells,34 expression of many of the cell sur-
face markers for differentiation are quite low and not
informative for staging purposes, as they are KLF1 targets.
As a result, we assessed and compared the range of cellu-
lar morphologies in the d11 proliferating samples, and find
these are not significantly different (Figure 1C). 
Global dysregulation of erythroid genes in the CDA cell
Given the availability of cells from only a single patient,
we aimed to analyze cells at three time points to increase
the robustness of our data. As a result, the PBMC under-
went a 2-step culture: one for proliferation, with harvests
at d11 and d15; the second for differentiation started at
d11 and harvested after an additional five days. RNA was
isolated from all samples and analyzed for gene expres-
sion via deep RNA sequencing. Focusing our analysis on
selected targets, we find a radical alteration of gene
expression that covers cell cycle, membrane protein, and
globin switching deficits, all congruent with the pheno-
typic properties of CDA type IV cells (Figure 2). For exam-
ple, although expression of some cell surface molecules
(CD47, CD55, CD58) are minimally affected as noted
before by FACS analysis of primary patient cells4 (and thus
serve as controls), GYPA (CD235a) expression is dramati-
cally lower. This is mimicked by radically low levels of
KLF1-regulated structural proteins such as ICAM4, tropo-
modulin (TMOD1), and band 4.2 (EPB42), likely con-
tributing to the fragility of  patients’ red cells and their
membrane abnormalities. Transport proteins such as
anion transporter band 3 (SLC4A1), ion channel PIEZO1,
potassium-calcium channel KCNN4, ABC transporter
ABCB6, and aquaporin water channel AQP3 exhibit
extremely low levels of expression (Figure 2A). 
Cells from the CDA patient express high levels of g-glo-
bin, reaching approximately 90% of total globin (Online
Supplementary Figure S1A). With respect to regulation of
globin switching, two KLF1 targets that act as g-globin
repressors were checked.41-43 BCL11A levels are decreased
but not that of ZRF/Pokemon (ZBTB7A) (Figure 2B), sug-
gesting that the increase in g-globin follows derepression
as a result of the drop in BCL11A protein. Contributing to
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Figure 1. Morphological assessment. (A) Bone marrow aspirate of patient. (B) (Left) Cytospin of patient periph-
eral blood mononuclear cells after expansion for 11 days; (right) similar analysis for normal patient sample per-
formed in parallel. Analysis of multiple slides revealed abnormal nuclei in 42.7% of CDA cells, and 5.6% of nor-
mal cells. (C) Quantification via cellular morphology of wild-type (WT) and patient cells categorized as proery-
throblast (ProE), basophilic erythroblast (Baso), polychromatophillic erythroblast (Poly), or orthchromatic ery-
throblast (Ortho). Multiple cytospin slides from two experiments were separately quantified by two investigators.
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this phenotypic effect, even though both alleles are
expressed (Online Supplementary Figure S1B), total KLF1
expression is lower in the CDA erythroid cell (Figure 2B)
verified by direct RT-qPCR (data not shown).
Cell cycle effects are less straightforward to interpret.
Both cell cycle stimulators as well as inhibitors play
important roles at different stages of erythroid terminal
differentiation.18 In the present case (Figure 2C), E2F2 and
E2F4 levels are overall lower in the patient cells, while p21
(CDKN1A) is higher. Surprisingly in this context, TP53
levels are lower in the patient cells, suggesting that the
increase in p21 occurs independently of p53.44 Expression
of pro- or anti-apoptosis protein-coding genes are mini-
mally changed, with the exception of BCL2 and possibly
PIM1, whose levels are higher in the CDA cell. 
Given the phenotypic problems with nuclear extrusion,
bi-nuclei, and bridges, it is of interest that a number of
cytokinesis/mitosis proteins implicated in these cellular
processes such as pleckstrin (PLEK2) and TRIM58 are
lower in expression (Figure 2D). In a link to CDA type III
patients that express mutant KIF23, levels of this gene are
decreased (as also noted in the KLF1 hydrops patient).29
Other CDA-associated genes such as CDAN1 (type I) and
SEC23B (type II) are not significantly altered. 
Given the extent of disruption of  iron utilization in the
CDA type IV patients, we also queried this subset of
genes as well, and found varied effects (Figure 2E). For
example, erythroferrone (FAM132B), a regulator of hep-
cidin, is dramatically down-regulated in the CDA patient
(and thus different from CDA type II45), as are the transfer-
rin receptors (TFR2 and TFRC). Although levels of the iron
exporter ferroportin (SCL40A1) and the heme regulator
SLC48A1 are not significantly altered, this combination
likely leads to a net inability to mobilize and incorporate
iron and heme in the CDA patient, particularly when cou-
pled to the low expression of the ABCB6 gene (noted ear-
lier) that would decrease activity of this important por-
phyrin importer. These conditions could account for the
anisopoikilocytosis seen in spite of normal MCV. Ferritin
levels (FTL and FTH1) are increased, which may con-
tribute to the high levels of stored iron observed in the
patient. By the same token, increased heme oxygenase
(HMOX1) could account for the hyperbilirubinemia seen
in all patients with type IV CDA. Alternatively, increased
bilirubin may be secondary to hemolysis, with HMOX1
expression increased in response. These effects are remi-
niscent of those resulting from the mouse Nan mutation,
which contains a change in the same amino acid (albeit to
D) and leads to extensive iron and heme regulation disrup-
tion.33 
Differentiation deficits
To identify expression changes in the CDA cell during
the process of proliferation and differentiation, we com-
pared genes expressed ≥5 FPKM (Fragments Per Kilobase
of transcript per Million) in all samples. Individual Venn
comparisons reveal that the d11 and d15 proliferating
samples each overlap >72%, but the differentiation d5 set
does not continue this pattern, only overlapping approxi-
mately 55% (Figure 3A). This suggests that terminal differ-
entiation does not proceed normally in the CDA erythroid
cell. To more directly address this, we analyzed RNA
expression of our samples and compared it to that from
cells undergoing normal human erythropoiesis.39,46,47 At
KLF1 mutation in human anemia
haematologica | 2019; 104(12) 2375
Figure 2. Relative expression levels following RNA-seq analysis.
Fragments Per Kilobase of transcript per Million (FPKM)  expression val-
ues were obtained following erythroid proliferation [day d11 and d15]
and differentiation (d5) of normal (wild-type, WT) or patient (CDA) periph-
eral blood mononuclear cells  (Online Supplementary Table S1). The pro-
liferation/differentiation series is grouped together and color-coded
based on expression of single samples taken at each time point. Color-
coding was based on relative expression of samples within each group.
Genes were selected based on their importance in: (A) cell surface
expression, structural or membrane integrity; (B) β-like globin gene regu-
lation; (C) cell cycle and apoptosis; (D) cytokinesis and mitosis; and (E)
iron utilization and storage.  
A B
C
D
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stages of differentiation from CD34+ to the proerythrob-
last stage (‘cluster 16’),39 gene enrichment analysis of d11
proliferating WT cells unsurprisingly shows a strong over-
lap with genes that are highest in the proerythroblast cell
(Figure 3B). However, this is not the case with the CDA
cells, which show a negative correlation (Figure 3B). In
fact, the CDA cells show a positive correlation with genes
that are highest at the CD34+ stage (‘cluster 1')39 (Figure
3B). Once CDA cells are differentiated at d5, they show a
slight increase in overlap with genes expressed late (brack-
eted region in Figure 3B). 
As an aid to visualize subsequent erythroid maturation
changes in expression, a heat map analysis was performed
with genes increasing in expression between the proery-
L. Varricchio et al.
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Figure 3. CDA cells are defective in differentiation. (A) Venn
diagrams of all genes expressed ≥5 Fragments Per Kilobase of
transcript per Million (FPKM)  and compared between prolifer-
ation day [d11, d15, or differentiation d5 samples, derived
from normal (wild-type, WT) or patient (CDA)]. (B) Gene set
enrichment analysis (GSEA) analysis of WT or CDA patient sam-
ples as indicated from proliferating d11 (P d11) or after differ-
entiation (Diff d5) were compared to genes enriched for expres-
sion either at late (‘cluster 16’, n=268) or early (‘cluster 1’,
n=174) stages of the CD34+/BFU-E/CFU-E/proerythroblast
series as identified by Li et al.39 (shown as insets in each graph).
Red brackets in the CDA samples show the increase in positive
overlap with late expressing genes when comparing proliferat-
ing d11 to differentiation d5 samples. Inserts are heat maps of
cluster 16 or cluster 1 from  Li et al.39 ES:  enrichment score. (C)
Heat map analysis of WT or CDA patient samples in conjunction
with a differentiation series (proerythroblast through to
orthochromatic erythroblast as indicated).46 The starting set
was ‘cluster 16’ from (B). (D) Relative FPKM expression values
of GATA2 and RUNX1 from the proliferation/differentiation
series, grouped together and color-coded as in Figure 2.
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throblast and orthchromatic stages.46,47 Starting from the
dataset of genes that are highest in the proerythroblast
(‘cluster 16’ set in Figure 3B), we see that many of these
genes continue to increase in expression during the normal
erythroid lineage differentiation process (Figure 3C).
Focusing first on the WT series, we see that the d11 set is
most closely aligned with the polychromatic erythroblast
expression pattern (Figure 3C). Many of these genes then
decrease in expression upon further proliferation (d15),
but most obviously after differentiation is established.
The pattern for the CDA series is different in two signifi-
cant ways (Figure 3C). 1) The expression of this gene set
at d11 is quite low, consistent with its GSEA expression
analysis. 2) Although the d15 set is converging on the
polychromatic/orthochromatic erythroblast pattern, it
remains minimally changed even after differentiation. 
These data suggest that the CDA erythroid cell retains a
significant residual early proliferation expression pattern,
consistent with the erythroid hyperplasia seen in the CDA
type IV patients’ bone marrow.4,5,12,13 Further supporting
this, expression of early hematopoietic transcriptional
markers such as GATA2 and RUNX1 remain high in the
CDA samples (Figure 3D). We conclude that terminal dif-
ferentiation is aberrant and does not proceed properly in
the CDA erythroid cell; importantly, this follows from a
combination of both the presence of KLF1-E325K and a
hypomorphic level of total KLF1 RNA expression. 
Ectopic expression of non-erythroid genes
The E325K change in KLF1-CDA is at a critical amino
acid within the DNA recognition sequence. Based on
structural arguments10,14 as well as the precedent from the
Nan-KLF1 mutation at the same site (E339D),31,32 it is likely
that the change in KLF1-CDA confers recognition of atyp-
ical sites in the genome. This would lead to ectopic
expression of genes that are normally not expressed in the
erythroid cell. Substitution of a lysine for glutamate at
amino acid (aa) 325 alters the middle residue of the critical
“X,Y,Z” amino acids, which play determining roles in
DNA target site recognition.48,49 Based on the most parsi-
monious model, one may predict the K325 residue would
now recognize guanine on the G-rich strand and alter the
recognition sequence to 3’GGKGGGGGN5’. This would
be a significant change, as a pyrimidine (T or C) is normal-
ly present at the underlined site. 
To identify these potential ectopic targets, we over-
lapped data sets from a Venn analysis of all expressed
genes (≥5 FPKM) that are exclusive to CDA (i.e. not
expressed in WT) in proliferating d11, d15, and differenti-
ating d5 samples. This yields a unique set of 184 genes
(Figure 4A). Many of these are membrane proteins that are
normally enriched in lymphoid, dendritic, myeloid, or
monocyte cells. Perusal of the top 35 differentially
expressed of these show that red cell character and identi-
ty have been altered. 
One of the most far reaching results from analysis of the
Nan-KLF1 mutant was that the neomorphic expression
pattern32 led to systemic effects that altered the hemato-
logic properties of the mouse, including changes in levels
of specific proteins and cytokines in the serum and feed-
back inhibition of erythropoiesis.33 In the present case,
expression of the unique CDA genes is truly ectopic, as
they do not overlap genes up-regulated in the KLF1-defec-
tive hydrops erythroid cell29 (Figure 4B). The extent of the
level of misexpression of specific, normally non-erythroid
targets in the CDA cell is shown in Figure 4C. CCL13 is a
chemokine implicated in inflammation, with potential
respiratory issues. This connects it with LTC4S, which
codes for leukotriene synthase, a gene normally expressed
only in the lung whose product is also implicated in
inflammation and respiration. PDPN codes for podoplas-
min, also expressed in the lung but in addition implicated
in aberrant platelet aggregation. IL17RB is a protein that
binds to the IL17 receptor. These increases are not due to
a global dysregulation, as expression of genes adjacent to
those affected are not significantly changed (data not
shown). 
Of mechanistic interest, each of these genomic regions
(CCL13, LTC4S, PDPN, IL17RB) contain multiple copies of
the predicted novel recognition sequence that could
potentially be recognized by KLF1-E325K (Figure 4D). In
support of this idea, a recent study in the Siatecka lab,
based on a binding site-selection strategy for CDA zinc
fingers, demonstrates that each of these putative sites bind
in vitro to CDA-KLF1, but not WT KLF1, as judged by gel
shift assays (K Kulczynska et al., 2019, submitted manu-
script). 
IL17RB is critical for expression of IL8 (CXCL8), a mole-
cule that, if mis-expressed, could have systemic effects
beyond the erythroid cell, particularly with respect to neu-
trophil activation and respiratory inflammation50,51 (analo-
gous to the misexpression of IFNβ in the Nan-KLF1 ery-
throid cell).33 We find that IL8 RNA expression levels are
quite high in the CDA samples, but not detectable in the
WT (Figure 4C). Consistent with the model, the CXCL8
genomic region does not contain potential ectopic binding
sites for CDA-KLF1 (data not shown) and thus is likely indi-
rectly activated by KLF1 through IL17RB. 
We conclude that these and other ectopic targets are
mis-expressed in the CDA erythroid cell by virtue of
expression of KLF1-E325K and its action via its novel
recognition site.
Discussion
Altered erythroid biology in the CDA patient cell
A mutation in KLF1, at E325K, is responsible for CDA
type IV. Seven patients have been described so far, and
they all share some similar phenotypic and clinical charac-
teristics.4-13 However, changes of RNA expression within
these patients’ erythroid cells has not been previously
described. This is of interest as type IV is unique among
CDA in that it is a transcription factor, rather than a struc-
tural protein, that is mutated.1,3 We find a major alteration
in the normal patterns of red cell gene expression, such
that globin regulation, cell surface protein expression,
membrane transport, cytokinesis, and iron utilization are
all dramatically affected. These transcriptional effects go
far in explaining the common patient phenotypes
described in the literature. 
However, a cautionary note must be acknowledged,
stemming from the limitation that we could only analyze
samples from one patient due to the rarity of the disease.
The question is whether our documented changes could
be due to inter-individual variation and/or whether we are
comparing equivalent stages. This is a general question in
the field that needs to be considered (e.g. as extensively
discussed),52-54 particularly with respect to difficulties in
finding the best way to compare patient/normal popula-
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Figure 4. Ectopic expression in CDA samples. (A) Venn diagram showing overlap between genes uniquely expressed in CDA proliferation day (d)11 (d11U), d15 (d15U),
and differentiation d5 (diff 5U) samples (Online Supplementary Table S2). DAVID analysis of terms enriched in the triple overlap between these samples (184 genes
total) is shown, as are the top 35 genes most highly expressed in this enriched set. (B) Venn diagram of genes whose expression increases in the absence of KLF129
compared to the CDA-unique gene list from (A). (C) Relative Fragments Per Kilobase of transcript per Million (FPKM) expression values of four of the top CDA-unique
genes of the proliferation/differentiation series grouped together and color-coded as in Figure 2. Also included are data for CXCL8 (IL8), which is downstream target of
IL17RB. (D) Genome browser layouts of the CDA-unique genes showing the location of perfect nucleotide matches to the novel consensus sequence potentially bound
by KLF1-E325K (5’CCMCCCCCN3’ on the C-rich strand). 
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tions of diseased cells, whether derived from individual
patients or from a more extended grouping. To surmount
this, we took care in our reliance on morphological assess-
ment and global expression evaluation and comparisons,
particularly given the limitations with respect to flow
analysis of surface differentiation markers. Importantly,
the observation that our patient’s cells have difficulty in
establishing differentiation in culture has been noticed in
another patient.13 The only solution to this dilemma is to
analyze additional patients, and/or to establish a ready
source of cells (e.g. induced pluripotent stem cells from the
patient) so that, at least, technical replicates can be more
easily generated and analyzed. 
As only BCL11A, but not ZBTB7A, levels were affected
in the patient samples, it may be surprising that g-globin
accounted for up to 90% of total β-like globin in our
analysis, given that the present patient’s HbF levels were
42%.5 However, erythroid cells in culture may not exactly
mimic the in vivo situation; for example, shRNA knock-
down of ZBTB7 in differentiating human erythroblasts led
to near 90% g-globin levels.55 
KLF1 ablation in the mouse leads to increased
megakaryocyte colony-forming potential and gene
expression (at the expense of erythropoiesis) as part of its
role in regulating bipotential lineage decisions in the
MEP.56-60 We do not find a similar increase in expression of
megakaryocyte-restricted genes61 (Online Supplementary
Figure S2). Although the CDA patient cells have higher
levels of FLI1 and PECAM expression, these likely follow
from differentiation deficits rather than lineage diver-
gence. 
Patients who are compound heterozygous for KLF1
mutations present with non-spherocytic hemolytic ane-
mia.27 In the present case, the extensive disruption of struc-
tural and transport membrane proteins explain the mem-
brane fragility and may also account for the low number
of cells obtained during differentiation, when the acquisi-
tion of the erythroid-specific cell membrane structure is
essential for survival.62,63 This is a suboptimal situation that
not only explains the hemolysis but also the apparent lack
of differentiation seen in the CDA cultures and in the
patient, and could also explain the lowered red cell sur-
vival.6,8 In other words, rather than resulting solely from a
differentiation block, the anemia and apparent hyperpla-
sia may follow the physical survival and preferential
enrichment of immature cells in the CDA patient.
Mechanistic implications of the E325K substitution
The dominant effect of KLF1-E325K expression follows
from mutation of only one allele that is sufficient to pro-
duce the altered genetic and cellular properties of the CDA
red cell. Our data suggest this follows from two different
causes. First, recognition by KLF1-E325K of its normal
cognate site is impaired;4,10 indeed, a quantitative reduc-
tion at all tested promoters by KLF1-E325 has been
observed10 (K Kulczynska, 2019, submitted manuscript). KLF1
is known to interact with transcriptional regulators, his-
tone modification proteins, and chromatin remodelers,17
and is critical for formation of the proper 3D chromatin
complex and transcription factories at a number of ery-
throid target sites.64,65 Accordingly, altered downstream
consequences in the CDA cell may well follow from
destabilized or incorrect protein complex formation that
interferes with optimal WT activity.10
This effect is likely augmented/intensified by our sec-
ond major observation that total KLF1 RNA levels are low.
Hypomorphic levels of KLF1 are known to negatively
affect expression of only a minority of selected targets,
and these effects appear phenotypically benign.19,23-25
However, in the present scenario low expression has been
compounded by co-expression of a mutant allele. The
sum of these changes is a dramatically dysregulated ery-
throid cell with altered physical and expression parame-
ters. 
It is instructive to compare our data with that from the
Nan mouse.31,66 Although the amino acid substitution is
different, this mouse is anemic by virtue of intrinsic red
cell parameters that are changed, many in a similar way to
that of the CDA type IV patient. However, there are two
fundamental differences. 1) The most obvious difference
is that a substitution of lysine for glutamic acid (in our
patient) is not expected to yield the same effect as substi-
tution of aspartic acid (in the Nan mouse), as the location
of this change is at a critical DNA recognition amino acid
in the zinc finger structure. 2) The more subtle corollary of
this is that the Nan mutation only affects a subset of its
normal 5’CCMCRCCCN3’ target sites (because Nan-
KLF1 still recognizes 5’CCMCGCCCN3’); as a result,
many KLF1 targets are not affected in the Nan erythroid
cell.31 This is less the case in the present situation, as the
lysine substitution in KLF1-E325K would not favor recog-
nition of a sequence with “R” in the middle position.10,32,48,49
However, one important concept derived from the Nan
mouse is directly relevant to the CDA erythroid cell: that
any amino acid change at this critical glutamic acid residue
(to D or to K) leads to recognition of an abnormal target
sequence, and thus ectopic expression of genes normally
not present in the red cell.32 Such misexpression in the Nan
mouse led to measurable and physiologically effective lev-
els of secreted proteins in the serum that contributed to its
splenomegaly and anemia.33 We suggest a similar occur-
rence here that could contribute to some of the non-ery-
throid characteristics (short stature, gonadal dysgenesis)
observed in many of the CDA type IV patients. Some of
the most highly dysregulated genes described here predict
that it might be useful to monitor respiratory and/or
autoimmune/inflammatory issues in CDA patients.50,51,67 In
this context, it will be of interest to compare RNA expres-
sion profiles of as many of the other patients as possible,
particularly with respect to gender differences and identi-
fication of potential modifier loci that affect the other,
non-shared phenotypes of the CDA type IV patients.13
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